What is the clinical evidence from this study?

Study design: Other. Population: Hypertrophic cardiomyopathy (n=2). Intervention: Generation of induced pluripotent stem cell (iPSC) lines. Primary outcome: iPSC line characterization (morphology, karyotype, pluripotency markers, trilineage differentiation).

What does this research mean for the field?

Patient-specific induced pluripotent stem cell lines carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA) maintain normal morphology and pluripotency, providing a viable platform for modeling hypertrophic cardiomyopathy. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to generate induced pluripotent stem cell lines from HCM patients with MYBPC3 mutations.

April 3, 2026Stem Cell ResearchOpen Access

Generation of two induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYBPC3 mutations

View Full Paper

Ask AI

Bookmark

Key result

Two iPSC lines generated from patients with MYBPC3-associated HCM display normal morphology and pluripotency.

Why the study?

Mutations in MYBPC3 are a leading cause of hypertrophic cardiomyopathy, and patient-specific stem cell lines were needed to enable disease modeling, mechanistic studies, and therapeutic investigations.

Population

Patients carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA)

Design

Preclinical cell line generation study

Authors

CWCatherine A. WuCardiovascular Institute of the South MWMatthew A. WuCardiovascular Institute of the South SZShane R. ZhaoCardiovascular Institute of the South

Discussion

Member takes

Implication

Should not yet change HCM practice; extends patient-specific iPSC platform for MYBPC3 mechanistic and therapeutic studies.

Key Points

The aim is to generate induced pluripotent stem cell lines from HCM patients with MYBPC3 mutations.
Generated iPSC lines from peripheral blood mononuclear cells of HCM patients.
Characterized the cell lines for morphology, karyotype, and pluripotency markers.
Assessed differentiation potential into three germ layers.
Both iPSC lines exhibited normal morphology and stable karyotypes.
High expression of pluripotency markers was observed in the iPSC lines.
The lines demonstrated robust trilineage differentiation potential.

Structured PICO

Population

Peripheral blood mononuclear cells from patients with hypertrophic cardiomyopathy (HCM) carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA)

Intervention

Generation of induced pluripotent stem cell (iPSC) lines

Outcome

Successful generation of iPSC lines with normal morphology, stable karyotypes, robust expression of pluripotency markers, and trilineage differentiation potentialsurrogate

The generation of these patient-specific iPSC lines provides a valuable platform for modeling MYBPC3-associated hypertrophic cardiomyopathy and enabling mechanistic and therapeutic studies.

Cite This Study

Wu et al. (2026) studied Hypertrophic cardiomyopathy (n=2). Generation of induced pluripotent stem cell (iPSC) lines was evaluated on iPSC line characterization (morphology, karyotype, pluripotency markers, trilineage differentiation). Two induced pluripotent stem cell lines from patients with MYBPC3-associated hypertrophic cardiomyopathy were successfully generated, displaying normal morphology and pluripotency.

synapsesocial.com/papers/69cf5f505a333a821460e5da https://doi.org/10.1016/j.scr.2026.103982

Topics

Hypertrophic cardiomyopathy

View Full Paper

Ask AI

Bookmark

Generation of two induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYBPC3 mutations

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Generation of two induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYBPC3 mutations

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider